Statements (169)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:acquired_by |
gptkb:Roche
|
| gptkbp:acquisition_year |
gptkb:2009
|
| gptkbp:awards |
gptkb:Fortune_100_Best_Companies_to_Work_For
numerous industry awards Best Workplaces for Parents Best Workplaces for Diversity Best Workplaces for Women Best Workplaces for Millennials Best Workplaces in Biotechnology Top 50 Employers for Diversity Best Places to Work in the Bay Area |
| gptkbp:benefits |
comprehensive employee benefits
|
| gptkbp:biologics |
focus on biologics development
|
| gptkbp:biotech_community |
active member of the biotech community
|
| gptkbp:ceo |
gptkb:Alexander_Hardy
gptkb:Arthur_D._Levinson |
| gptkbp:clinical_trial |
ongoing
post-marketing studies Phase III trials Phase I trials Phase II trials invests heavily in clinical research conducts clinical trials globally utilizes clinical data for research FDA approvals |
| gptkbp:collaborations |
collaborates with various research organizations
|
| gptkbp:community_engagement |
STEM education initiatives
employee volunteer programs environmental sustainability efforts healthcare access programs patient advocacy support |
| gptkbp:community_involvement |
educational initiatives
environmental sustainability efforts philanthropy programs |
| gptkbp:employees |
approximately 13,000
13,000 (2020) |
| gptkbp:employs |
approximately 13,000 people
|
| gptkbp:financial_support |
provides patient support programs
|
| gptkbp:first_drug_approved |
gptkb:Kineret
gptkb:1985 |
| gptkbp:founded |
gptkb:1976
|
| gptkbp:founded_by |
gptkb:Robert_Swanson
gptkb:Herbert_Boyer |
| gptkbp:founded_in |
gptkb:1976
|
| gptkbp:founder |
gptkb:Herbert_W._Boyer
gptkb:Robert_Swanson gptkb:Robert_E._Swanson gptkb:Herbert_Boyer |
| gptkbp:funding |
gptkb:1980
significant research funding |
| gptkbp:global_presence |
global supply chain management
operates in multiple countries collaborations in Asia collaborations in Europe collaborations in Latin America has a global presence in healthcare |
| gptkbp:has_culture |
innovative work culture
|
| gptkbp:has_research_center |
gptkb:Australia
gptkb:Austria gptkb:Belgium gptkb:Brazil gptkb:Canada gptkb:China gptkb:Denmark gptkb:Finland gptkb:France gptkb:Germany gptkb:Hungary gptkb:India gptkb:Ireland gptkb:Israel gptkb:Italy gptkb:Japan gptkb:Netherlands gptkb:North_Carolina gptkb:Norway gptkb:Oregon gptkb:Poland gptkb:Portugal gptkb:Russia gptkb:Saudi_Arabia gptkb:Singapore gptkb:South_Africa gptkb:Spain gptkb:Sweden gptkb:Switzerland gptkb:Turkey gptkb:United_Arab_Emirates gptkb:United_Kingdom gptkb:San_Francisco_Bay_Area gptkb:Czech_Republic |
| gptkbp:headcount |
13,000+
|
| gptkbp:headquarters |
gptkb:South_San_Francisco,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Genentech
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:innovation |
collaborative research initiatives
investment in research and development development of biosimilars focus on biotechnology advancements patents in biopharmaceuticals drives innovation in healthcare |
| gptkbp:invention |
numerous patents in biotechnology
|
| gptkbp:key_people |
gptkb:Bill_Anderson
gptkb:Art_Levinson |
| gptkbp:known_for |
monoclonal antibodies
recombinant DNA technology |
| gptkbp:leadership |
diverse leadership team
|
| gptkbp:market_cap |
approximately $100 billion
|
| gptkbp:notable_achievement |
pioneered the field of biotechnology
first company to produce a recombinant human insulin developed the first monoclonal antibody for cancer treatment |
| gptkbp:notable_products |
gptkb:Avastin
gptkb:Emicizumab gptkb:Herceptin gptkb:Lucentis gptkb:Rituxan gptkb:Xolair |
| gptkbp:notable_work |
personalized medicine
targeted therapies monoclonal antibodies biologics recombinant DNA technology |
| gptkbp:part_of |
gptkb:Roche_Group
|
| gptkbp:partnerships |
gptkb:Harvard_University
gptkb:Stanford_University gptkb:University_of_California,_San_Francisco gptkb:MIT gptkb:Scripps_Research_Institute various academic institutions other pharmaceutical companies |
| gptkbp:philanthropy |
gptkb:Genentech_Foundation
community health initiatives education programs research grants employee volunteer programs |
| gptkbp:produces |
biopharmaceuticals
|
| gptkbp:products |
gptkb:Avastin
gptkb:Tecentriq gptkb:Perjeta gptkb:Herceptin gptkb:Lucentis gptkb:Rituxan gptkb:Xolair gptkb:Ocrevus |
| gptkbp:publications |
publishes scientific research
|
| gptkbp:research_focus |
gptkb:Oncology
cardiology metabolic disorders neurology oncology autoimmune diseases neuroscience cardiovascular diseases infectious diseases immunology ophthalmology |
| gptkbp:revenue |
$11.5 billion
$26.1 billion (2020) |
| gptkbp:side_effect |
significant impact on healthcare
|
| gptkbp:stock_symbol |
gptkb:DNA
|
| gptkbp:subsidiary |
gptkb:Roche_Holding_AG
|
| gptkbp:sustainability |
committed to sustainability practices
|
| gptkbp:therapeutics |
develops targeted therapeutics
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:uses_technology |
leader in biotechnology industry
|
| gptkbp:website |
www.gene.com
|
| gptkbp:bfsParent |
gptkb:biotechnology
|
| gptkbp:bfsLayer |
3
|